IDEAYA Biosciences, Inc.
NASDAQ:IDYABiotechnology
-$0.45 today
- Market cap
- $2.56B
- Beta
- -0.05
- P/E (TTM)
- -19.5
- EPS (TTM)
- -$1.58
Volume 1.45M
Average 1.44M
IDYA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
IDEAYA Biosciences, Inc.NASDAQ: IDYA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $1.14M rose 0.9% year over year, behind the +18.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.5% from the prior quarter. Over 3 fiscal years it compounded at +29.8% a year.
Context
- Depreciation & amortization amounted to 2.1% of revenue in FY2025, down 52.7 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.9% toward the trailing-twelve-month pace of +18.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 4.59M USD
- Year-over-year change
- +19.8%
- 4-year CAGR
- +27.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.59M | +19.8% |
| FY2024 | 2024-12-31 | 3.83M | -4.3% |
| FY2023 | 2023-12-31 | 4.01M | +90.8% |
| FY2022 | 2022-12-31 | 2.1M | +21.8% |
| FY2021 | 2021-12-31 | 1.73M | — |
Depreciation & Amortization vs competitors
How IDYA compares with its peers on the latest reported figures
- IDYA's LTM Mar 2026 depreciation & amortization of $4.6M is the 3rd highest of the 9 companies compared; the peer median is $2.84M.
- Its year-over-year change of +18.5% is the 3rd highest of 9, against a peer median of -8.2%.
- Depreciation & amortization amounts to 2.0% of revenue for IDYA, versus a peer median of 6.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $18.08M | +31.1% | +19.7% | — | |
| LTM Aug 2026 | $14.4M | -22.3% | +20.4% | 2.1% | |
| LTM Mar 2026 | $4.6M | +18.5% | +29.8% | 2.0% | |
| LTM Jun 2026 | $4.18M | -7.0% | -8.0% | — | |
| LTM Sep 2026 | $2.89M | -9.4% | +5.6% | — | |
| LTM Mar 2026 | $2.79M | -10.3% | +0.1% | 9.9% | |
| LTM Sep 2026 | $1.79M | -26.2% | +12.4% | — | |
| LTM Mar 2026 | $1.67M | -6.4% | +8.9% | 10.0% | |
| LTM Mar 2026 | $997K | +3223.3% | +83.4% | 2.0% | |
| Peer median (excluding IDYA) | $2.84M | -8.2% | +10.6% | 6.0% | |
Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.94M | 50.93M | 23.39M | 7M | 218.71M |
| Cost of Revenue | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M |
| Gross Profit | 26.22M | 48.83M | 19.38M | 3.17M | 214.12M |
| Gross Margin | 93.8% | 95.9% | 82.9% | 45.2% | 97.9% |
| Research & Development | 58.16M | 89.54M | 129.51M | 294.67M | 314.7M |
| Selling, General & Admin | 18.33M | 21.8M | 24.3M | 35.47M | 63.32M |
| Operating Expenses | 76.48M | 111.33M | 153.81M | 330.14M | 373.43M |
| Depreciation & Amortization | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M |
| EBITDA | (48.04M) | (56.55M) | (108.95M) | (270.64M) | (109.11M) |
| EBITDA Margin | -171.9% | -111.0% | -465.9% | -3866.3% | -49.9% |
| Operating Income | (50.27M) | (62.5M) | (134.43M) | (326.98M) | (159.31M) |
| Operating Margin | -179.9% | -122.7% | -574.9% | -4671.1% | -72.8% |
| Interest Income | 506K | 3.85M | 21.47M | 52.5M | 45.62M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 506K | 3.85M | 21.47M | 52.5M | 45.62M |
| Income Before Tax | (49.76M) | (58.66M) | (112.96M) | (274.48M) | (113.7M) |
| Pre-Tax Margin | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (49.76M) | (58.66M) | (112.96M) | (274.48M) | (113.7M) |
| Net Margin | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| EPS (Basic) | (1.41) | (1.42) | (1.96) | (3.36) | (1.28) |
| EPS (Diluted) | (1.41) | (1.42) | (1.96) | (3.36) | (1.28) |
| Weighted Avg Shares | 35.25M | 41.44M | 57.52M | 81.68M | 88.49M |
| Weighted Avg Shares (Diluted) | 35.25M | 41.44M | 57.52M | 81.68M | 88.49M |
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
Intrinsic Alpha fair value
Locked
Current Price
$26.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.